Cefroxadine(CGP-9000)に関する基礎的ならびに臨床的研究 (Cefroxadine(CGP-9000,CXD)<特集>)
スポンサーリンク
概要
- 論文の詳細を見る
The antibacterial activity of Cefroxadine (CGP-9000, CXD) against clinical isolates was microbiologically determined, and also its therapeutic efficacy in infections in the field of internal medicine was studied.<BR>The peak of susceptibility which CXD has shown, with a small inoculum size, against <I>S. aureus, E. coli</I>, <I>Klebsiella, P. vulgaris</I>, and <I>P. vulgaris</I> isolated from pathological specimens was distributed at 3.12μg, 6.25μg, 3.12μg, 6.25-12.5μg and above 100μg per ml, respectively. The antibacterial action of CXD against <I>S. aureus</I> was almost equal to that of CEX. Despite its less potent activity than CEX against <I>P. vulgaris</I>, CXD was proven to be about twice more active than CEX against <I>E. coli, Klebsiella</I>, and <I>P. mirabilis</I>.<BR>A dose of 750 mg of CXD daily (For one case, 1, 500 mg daily was given) was administered to a total of 13 cases consisting of 7 cases of acute pharyngitis, 4 cases of acute bronchitis, 1 case of bronchial pneumonia associated with infection and 1 case of acute cystitis. The clinical responses obtained by this drug were effective in 10 cases, slightly effective in 2 and ineffective in the remaining 1 case. Any specific adverse reactions were not observed.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.